MicuRx To Present New Data At 7th World Bronchiectasis Conference

2024-06-19

临床1期微生物疗法

SHANGHAI, June 19, 2024 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH), a multi-asset biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced 3 new studies will be presented at the 7th World Bronchiectasis Conference, taking place from July 4 - 6, 2024 in Dundee, Scotland. The presentations will showcase nonclinical data for MRX-5 and MRX-8. MRX-5 is an oral investigational candidate for the treatment of adults with nontuberculous mycobacteria (NTM) pulmonary diseases. MRX-5 demonstrates potent antimicrobial activity against Mycobacterium avium complex (MAC), the most common NTM pathogen, as well as Mycobacterium abscessus complex (MABC), the more difficult-to-treat NTM. MRX-5 is currently in Phase 1 clinical studies and topline results are expected in late 3Q2024. MRX-8 is a novel compound in the polymyxin class. Nebulized MRX-8 is developed for treating chronic Pseudomonas aeruginosa lung infection in patients with bronchiectasis, including infections caused by drug resistant isolates. Presentations pertaining to MRX-5 and MRX-8: Title: In Vitro And In Vivo Activity Of A Novel Leucyl-Trna Synthetase Inhibitor Against Mycobacterium Abscessus Presenting Author: Regis Vilchez, MD, PhD (MicuRx) Title: In Vitro Activity of Novel Leucyl-tRNA Synthetase Inhibitor Against Mycobacterium Avium Complex Presenting Author: Wen Wang, PhD (MicuRx) Title: In Vitro And In Vivo Activity Of A Novel Antibiotic In The Polymyxin Class Against Pseudomonas Aeruginosa Presenting Author: Wen Wang, PhD (MicuRx) About MicuRx MicuRx is a biopharmaceutical company focusing on novel therapeutics for infectious diseases. With global independent intellectual property and competitiveness, we are committed to the discovery, development, and commercialization of innovative drugs for unmet medical needs. Since the company was founded in 2007, MicuRx has adhered to the principle of "Better therapy through superior medicine", focusing on the increasingly serious problem of global antimicrobial resistance. For more information, please visit our website at View original content to download multimedia: SOURCE MicuRx Pharmaceuticals Company Codes: Shanghai:688373

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构